BioSenic signs a new subscription agreement for a maximum of EUR 1.2M in convertible bonds Mont-Saint-Guibert, Belgium, January 8, 2024, 6pm CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the company addressing unmet medical needs in auto-immune diseases and orthopedics, today announces that it has signed a new subscription agreement for a maximum EUR 1.2 million convertible bonds ("CBs") facility, arranged by ABO Securities through its affiliated entity Global Tech Opportunities 15 ("GTO